ALK (D5F3) CDx: An Immunohistochemistry Assay to Identify ALK-positive NSCLC Patients

Pharmacogenomics and Personalized Medicine - New Zealand
doi 10.2147/pgpm.s156672
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Crizotinib-Associated Toxic Epidermal Necrolysis in an ALK-positive Advanced NSCLC Patient

Molecular and Clinical Oncology
Cancer ResearchOncology
2018English

Variable Response to ALK Inhibitors in NSCLC With a Novel MYT1L-ALK Fusion

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

Brigatinib Bei ALK-positivem NSCLC

Im Focus Onkologie
2017English

P2.13-06 TP53 Status in Relation to Response to Anti-Alk Agents in Patients With EML4-ALK-Translocated NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Alectinib Provides a New Option for ALK-positive NSCLC Patients After Progression on Crizotinib

Journal of Community and Supportive Oncology
OncologyHematology
2016English

MA26.01 Accumulation of Concomitant Mutations Involved in Drug Resistance in the Sequential ALK TKI Treatments of ALK-Positive NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Neue Chance Bei ALK-positivem NSCLC

Info Onkologie
2013English

P1.01-101 Survival Benefit of Sequential Therapy in ALK Positive Olioprogressive NSCLC Patients After Crizotinib Resistance

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Pcn216 - Contemporary Real-World Evidences on Alk+ NSCLC Patients in Italy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy